A recent study paints 340B program participants in a negative light, suggesting that covered entities chase profits and experience windfalls rather than help patients. However, these assumptions are far from true.
The 340B program is critical for hospitals and other providers that serve some of our country's poorest and most vulnerable patients. When providers monitor compliance and track 340B drugs properly, the program can fulfill its intended purpose.